Protalix BioTherapeutics, Inc. (DE) (PLX): Price and Financial Metrics
Protalix BioTherapeutics, Inc. (DE) (PLX)
Today's Latest Price: $4.46 USD
Updated Jan 25 6:40pm
Add PLX to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
See all "A" rated Strong Buy stocks
PLX Stock Summary
- The capital turnover (annual revenue relative to shareholder's equity) for PLX is -1.84 -- better than merely 4.12% of US stocks.
- Equity multiplier, or assets relative to shareholders' equity, comes in at -1.61 for Protalix BioTherapeutics Inc; that's greater than it is for merely 5.22% of US stocks.
- Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for PLX comes in at -27.08% -- higher than that of just 9.89% of stocks in our set.
- Stocks that are quantitatively similar to PLX, based on their financial statements, market capitalization, and price volatility, are AGEN, ABUS, OMER, GNFT, and DNN.
- Visit PLX's SEC page to see the company's official filings. To visit the company's web site, go to www.protalix.com.
PLX Stock Price Chart Interactive Chart >
PLX Price/Volume Stats
| Current price | $4.46 | 52-week high | $4.86 |
| Prev. close | $4.58 | 52-week low | $2.04 |
| Day low | $4.46 | Volume | 203,500 |
| Day high | $4.59 | Avg. volume | 247,580 |
| 50-day MA | $3.73 | Dividend yield | N/A |
| 200-day MA | $3.61 | Market Cap | 148.68M |
Protalix BioTherapeutics, Inc. (DE) (PLX) Company Bio
Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system in Israel and internationally. The company was founded in 1993 and is based in Carmiel, Israel.
Loading social stream, please wait...